Loading clinical trials...
Loading clinical trials...
The primary objective of this Phase II study is to evaluate the use of labelled RGD ligand in PET/CT to predict and/or to early assess the efficacy of chemotherapy including an agent with antiangiogen...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT04491942 · Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, and more
NCT07072325 · Malignant Neoplasm, Head &Amp; Neck Cancer, and more
NCT03727061 · Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
Hôpital Tenon - Assistance Publique-Hôpitaux de Paris
Paris
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions